

# Guosheng Yin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8749048/publications.pdf>

Version: 2024-02-01

144  
papers

3,960  
citations

136950

32  
h-index

144013

57  
g-index

157  
all docs

157  
docs citations

157  
times ranked

3767  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials. <i>Biostatistics</i> , 2023, 24, 277-294.	1.5	7
2	Bayesian Nonparametric Analysis of Restricted Mean Survival Time. <i>Biometrics</i> , 2023, 79, 1383-1396.	1.4	0
3	Bayesian Hierarchical Model for Change Point Detection in Multivariate Sequences. <i>Technometrics</i> , 2022, 64, 177-186.	1.9	3
4	CFO: Calibration-free odds design for phase I/II clinical trials. <i>Statistical Methods in Medical Research</i> , 2022, 31, 1051-1066.	1.5	3
5	C-index regression for recurrent event data. <i>Contemporary Clinical Trials</i> , 2022, 118, 106787.	1.8	9
6	Reconnecting $p$ -Value and Posterior Probability Under One- and Two-Sided Tests. <i>American Statistician</i> , 2021, 75, 265-275.	1.6	19
7	Dynamic ordering design for dose finding in drug-combination trials. <i>Pharmaceutical Statistics</i> , 2021, 20, 348-361.	1.3	0
8	Sample size re-estimation in adaptive enrichment design. <i>Contemporary Clinical Trials</i> , 2021, 100, 106216.	1.8	0
9	Bayesian Hierarchical Modeling and Biomarker Cutoff Identification in Basket Trials. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 248-258.	0.8	6
10	Reduction in number to treat versus number needed to treat. <i>BMC Medical Research Methodology</i> , 2021, 21, 48.	3.1	1
11	Concordance index: Surrogacy of progression-free survival for overall survival. <i>Contemporary Clinical Trials</i> , 2021, 104, 106353.	1.8	3
12	The global, regional, and national burden of cancer among adolescents and young adults in 204 countries and territories, 1990-2019: a population-based study. <i>Journal of Hematology and Oncology</i> , 2021, 14, 89.	17.0	21
13	Response-Adaptive Rerandomization. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2021, 70, 1281-1298.	1.0	1
14	Unit information prior for adaptive information borrowing from multiple historical datasets. <i>Statistics in Medicine</i> , 2021, 40, 5657-5672.	1.6	7
15	Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Public Health</i> , 2021, 9, 729559.	2.7	27
16	Demystify Lindley's paradox by connecting $p$ -value and posterior probability. <i>Statistics and Its Interface</i> , 2021, 14, 489-502.	0.3	1
17	Principles and Reporting of Bayesian Trials. <i>Journal of Thoracic Oncology</i> , 2021, 16, 30-36.	1.1	1
18	Convergence rates of the blocked Gibbs sampler with random scan in the Wasserstein metric. <i>Stochastics</i> , 2020, 92, 265-274.	1.1	0

#	ARTICLE	IF	CITATIONS
19	Functional Censored Quantile Regression. <i>Journal of the American Statistical Association</i> , 2020, 115, 931-944.	3.1	8
20	The Delaunay triangulation learner and its ensembles. <i>Computational Statistics and Data Analysis</i> , 2020, 152, 107030.	1.2	10
21	Fractional design: An alternative paradigm for late-onset toxicities in oncology dose-finding studies. <i>Contemporary Clinical Trials Communications</i> , 2020, 19, 100650.	1.1	4
22	Restricted mean survival time for interval-censored data. <i>Statistics in Medicine</i> , 2020, 39, 3879-3895.	1.6	6
23	Bayesian enhancement two-stage design with error control for phase II clinical trials. <i>Statistics in Medicine</i> , 2020, 39, 4452-4465.	1.6	2
24	START: single-to-double arm transition design for phase II clinical trials. <i>Pharmaceutical Statistics</i> , 2020, 19, 454-467.	1.3	3
25	Adaptive iterative Hessian sketch via A-optimal subsampling. <i>Statistics and Computing</i> , 2020, 30, 1075-1090.	1.5	4
26	Comparison of Transmissibility of Coronavirus Between Symptomatic and Asymptomatic Patients: Reanalysis of the Ningbo COVID-19 Data. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e19464.	2.6	37
27	Coarse-To-Fine Framework For Music Generation via Generative Adversarial Networks. , 2020, , .		1
28	Ventilation prediction for ICU patients with LSTM-based deep relative risk model. , 2020, , .		0
29	A variable selection approach to multiple change-points detection with ordinal data. <i>Statistics and Its Interface</i> , 2020, 13, 251-260.	0.3	1
30	Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e19538.	2.6	3
31	Dynamic portfolio choice without cash. <i>Quantitative Finance</i> , 2019, 19, 313-326.	1.7	5
32	Design of Noninferiority Trials for Hypofractionated vs Conventional Radiotherapy Among Patients With Cancer. <i>JAMA Oncology</i> , 2019, 5, 1508.	7.1	0
33	An alternative approach for estimating the number needed to treat for survival endpoints. <i>PLoS ONE</i> , 2019, 14, e0223301.	2.5	7
34	Biostatistics pitfalls: Lessons learned from analysis of medical data. <i>Contemporary Clinical Trials</i> , 2019, 87, 105875.	1.8	3
35	Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies. <i>Circulation</i> , 2019, 140, 1366-1368.	1.6	56
36	Reanalysis of Data Comparing Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1638.	7.1	0

#	ARTICLE	IF	CITATIONS
37	Trends and Patterns of Disparities in Burden of Lung Cancer in the United States, 1974-2015. <i>Frontiers in Oncology</i> , 2019, 9, 404.	2.8	19
38	Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. <i>New England Journal of Medicine</i> , 2019, 380, e32.	27.0	4
39	Radical Surgery or Watchful Waiting in Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 1083-1084.	27.0	2
40	Nonparametric overdose control for dose finding in drug combination trials. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2019, 68, 1111-1130.	1.0	6
41	Multiple change-points detection in high dimension. <i>Random Matrices: Theory and Application</i> , 2019, 08, 1950014.	1.1	5
42	Bayesian Enhancement Two-Stage Design for Single-Arm Phase II Clinical Trials with Binary and Time-to-Event Endpoints. <i>Biometrics</i> , 2018, 74, 1055-1064.	1.4	9
43	Maximum likelihood estimation for incomplete multinomial data via the weaver algorithm. <i>Statistics and Computing</i> , 2018, 28, 1095-1117.	1.5	4
44	Two-stage seamless transition design from open-label single-arm to randomized double-arm clinical trials. <i>Statistical Methods in Medical Research</i> , 2018, 27, 158-171.	1.5	4
45	Censored cumulative residual independent screening for ultrahigh-dimensional survival data. <i>Lifetime Data Analysis</i> , 2018, 24, 273-292.	0.9	16
46	Boosting conditional logit model. <i>Journal of Choice Modelling</i> , 2018, 26, 48-63.	2.3	10
47	Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-Event Endpoint. <i>Statistics in Biosciences</i> , 2018, 10, 420-438.	1.2	7
48	Varying association copula models for multivariate survival data. <i>Canadian Journal of Statistics</i> , 2018, 46, 556-576.	0.9	1
49	AVERAGE HOLDING PRICE. <i>Annals of Financial Economics</i> , 2018, 13, 1850002.	1.4	0
50	Uniformly most powerful Bayesian interval design for phase I dose-finding trials. <i>Pharmaceutical Statistics</i> , 2018, 17, 710-724.	1.3	9
51	Bayesian optimal interval design for dose finding in drug-combination trials. <i>Statistical Methods in Medical Research</i> , 2017, 26, 2155-2167.	1.5	69
52	Partitioned log-rank tests for the overall homogeneity of hazard rate functions. <i>Lifetime Data Analysis</i> , 2017, 23, 400-425.	0.9	6
53	Bayesian randomized clinical trials: From fixed to adaptive design. <i>Contemporary Clinical Trials</i> , 2017, 59, 77-86.	1.8	33
54	Ensemble Approaches to Estimating the Population Mean with Missing Response. <i>Scandinavian Journal of Statistics</i> , 2017, 44, 899-917.	1.4	11

#	ARTICLE	IF	CITATIONS
55	Random Walk and Parallel Crossing Bayesian Optimal Interval Design for Dose Finding with Combined Drugs. , 2017, , 21-35.		0
56	Nonparametric overdose control with late-onset toxicity in phase I clinical trials. Biostatistics, 2017, 18, 180-194.	1.5	23
57	STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials. Statistics in Medicine, 2017, 36, 4106-4120.	1.6	41
58	Landmark cure rate models with time-dependent covariates. Statistical Methods in Medical Research, 2017, 26, 2042-2054.	1.5	11
59	Multiple Imputation for Cure Rate Quantile Regression with Censored Data. Biometrics, 2017, 73, 94-103.	1.4	7
60	Cure rate quantile regression accommodating both finite and infinite survival times. Canadian Journal of Statistics, 2017, 45, 29-43.	0.9	2
61	Bayesian Two-Stage Design for Phase II Clinical Trials with Switching Hypothesis Tests. Bayesian Analysis, 2017, 12, .	3.0	9
62	Bayesian Two-Stage Dose Finding for Cytostatic Agents Via Model Adaptation. Journal of the Royal Statistical Society Series C: Applied Statistics, 2016, 65, 465-482.	1.0	2
63	Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials. Annals of Applied Statistics, 2016, 10, .	1.1	8
64	Power computation for hypothesis testing with high-dimensional covariance matrices. Computational Statistics and Data Analysis, 2016, 104, 10-23.	1.2	1
65	Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer. American Journal of Pathology, 2016, 186, 2162-2170.	3.8	18
66	Generalized Method of Moments for Additive Hazards Model with Clustered Dental Survival Data. Scandinavian Journal of Statistics, 2016, 43, 1124-1139.	1.4	3
67	Comments on "Competing designs for drug combination in phase I dose-finding clinical trials" by MâK. Riviere, F. Dubois, and S. Zohar. Statistics in Medicine, 2015, 34, 13-17.	1.6	14
68	Phase I trial design for drug combinations with Bayesian model averaging. Pharmaceutical Statistics, 2015, 14, 108-119.	1.3	7
69	Outlier detection for high-dimensional data. Biometrika, 2015, 102, 589-599.	2.4	51
70	Detecting Overall Survival Benefit Derived From Survival Postprogression Rather Than Progression-Free Survival. Journal of the National Cancer Institute, 2015, 107, .	6.3	24
71	Smoothed and Corrected Score Approach to Censored Quantile Regression With Measurement Errors. Journal of the American Statistical Association, 2015, 110, 1670-1683.	3.1	18
72	Generalized partially linear single-index model for zero-inflated count data. Statistics in Medicine, 2015, 34, 876-886.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Bayes factor and posterior probability: Complementary statistical evidence to p-value. <i>Contemporary Clinical Trials</i> , 2015, 44, 33-35.	1.8	14
74	Conditional quantile screening in ultrahigh-dimensional heterogeneous data. <i>Biometrika</i> , 2015, 102, 65-76.	2.4	66
75	Inter-Ethnic/Racial Facial Variations: A Systematic Review and Bayesian Meta-Analysis of Photogrammetric Studies. <i>PLoS ONE</i> , 2015, 10, e0134525.	2.5	48
76	Two-stage adaptive randomization for delayed response in clinical trials. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2014, 63, 559-578.	1.0	6
77	Two-stage dose finding for cytostatic agents in phase I oncology trials. <i>Statistics in Medicine</i> , 2013, 32, 644-660.	1.6	12
78	Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints. <i>Contemporary Clinical Trials</i> , 2013, 36, 642-650.	1.8	31
79	Escalation with overdose control for phase I drug-combination trials. <i>Statistics in Medicine</i> , 2013, 32, 4400-4412.	1.6	30
80	Fractional Dose-Finding Methods with Late-Onset Toxicity in Phase I Clinical Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2013, 23, 856-870.	0.8	18
81	Cure Rate Quantile Regression for Censored Data With a Survival Fraction. <i>Journal of the American Statistical Association</i> , 2013, 108, 1517-1531.	3.1	19
82	Pearson-type goodness-of-fit test with bootstrap maximum likelihood estimation. <i>Electronic Journal of Statistics</i> , 2013, 7, 412-427.	0.7	9
83	Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity. <i>Annals of Applied Statistics</i> , 2013, 7, 1837-2457.	1.1	58
84	Testing overall and subpopulation treatment effects with measurement errors. <i>Statistica Sinica</i> , 2013, 23, 1019-1042.	0.3	0
85	Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization. <i>Clinical Cancer Research</i> , 2012, 18, 4498-4507.	7.0	56
86	A general transformation class of semiparametric cure rate frailty models. <i>Annals of the Institute of Statistical Mathematics</i> , 2012, 64, 959-989.	0.8	11
87	Phase II Trial Design with Bayesian Adaptive Randomization and Predictive Probability. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2012, 61, 219-235.	1.0	57
88	Robust EM Continual Reassessment Method in Oncology Dose Finding. <i>Journal of the American Statistical Association</i> , 2011, 106, 818-831.	3.1	54
89	Bayesian phase I/II adaptively randomized oncology trials with combined drugs. <i>Annals of Applied Statistics</i> , 2011, 5, 924-942.	1.1	56
90	Dose-Response Curve Estimation: A Semiparametric Mixture Approach. <i>Biometrics</i> , 2011, 67, 1543-1554.	1.4	17

#	ARTICLE	IF	CITATIONS
91	Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity. <i>Lifetime Data Analysis</i> , 2011, 17, 156-174.	0.9	9
92	Efficiency improvement in a class of survival models through model-free covariate incorporation. <i>Lifetime Data Analysis</i> , 2011, 17, 552-565.	0.9	7
93	Bayesian hybrid dose-finding design in phase I oncology clinical trials. <i>Statistics in Medicine</i> , 2011, 30, 2098-2108.	1.6	17
94	Methylation of the candidate biomarker <i>TCF21</i> is very frequent across a spectrum of early-stage nonsmall cell lung cancers. <i>Cancer</i> , 2011, 117, 606-617.	4.1	59
95	Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without $\text{CA}^{\text{CSF}}$ in Locally Advanced Breast Cancer: Long-Term Results. <i>Oncologist</i> , 2011, 16, 1527-1534.	3.7	29
96	Stochastic Generalized Method of Moments. <i>Journal of Computational and Graphical Statistics</i> , 2011, 20, 714-727.	1.7	9
97	Semiparametric median residual life model and inference. <i>Canadian Journal of Statistics</i> , 2010, 38, 665-679.	0.9	24
98	Bayesian Quantile Regression for Longitudinal Studies with Nonignorable Missing Data. <i>Biometrics</i> , 2010, 66, 105-114.	1.4	102
99	Glutathione-S-Transferase-Pi Expression in Early Breast Cancer: Association With Outcome and Response to Chemotherapy. <i>Cancer Investigation</i> , 2010, 28, 554-559.	1.3	24
100	Sex Determining Region Y-Box 2 (SOX2) Is a Potential Cell-Lineage Gene Highly Expressed in the Pathogenesis of Squamous Cell Carcinomas of the Lung. <i>PLoS ONE</i> , 2010, 5, e9112.	2.5	117
101	HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 4829-4837.	7.0	151
102	Generalized method of moments estimation for linear regression with clustered failure time data. <i>Biometrika</i> , 2009, 96, 293-306.	2.4	14
103	Least squares estimation of varying-coefficient hazard regression with application to breast cancer dose-intensity data. <i>Canadian Journal of Statistics</i> , 2009, 37, 659-674.	0.9	1
104	A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents. <i>Biometrics</i> , 2009, 65, 866-875.	1.4	98
105	Bayesian Dose Finding in Oncology For Drug Combinations by Copula Regression. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2009, 58, 211-224.	1.0	124
106	Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy as Time-to-Event Outcomes. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2009, 58, 719-736.	1.0	81
107	Bayesian goodness-of-fit test for censored data. <i>Journal of Statistical Planning and Inference</i> , 2009, 139, 1474-1483.	0.6	4
108	Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials. <i>Journal of the American Statistical Association</i> , 2009, 104, 954-968.	3.1	142

#	ARTICLE	IF	CITATIONS
109	Bayesian generalized method of moments. <i>Bayesian Analysis</i> , 2009, 4, .	3.0	38
110	Bayesian cure rate model accommodating multiplicative and additive covariates. <i>Statistics and Its Interface</i> , 2009, 2, 513-521.	0.3	1
111	Bayesian transformation cure frailty models with multivariate failure time data. <i>Statistics in Medicine</i> , 2008, 27, 5929-5940.	1.6	18
112	Sequential continual reassessment method for two-dimensional dose finding. <i>Statistics in Medicine</i> , 2008, 27, 5664-5678.	1.6	72
113	Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. <i>Cancer</i> , 2008, 112, 1455-1461.	4.1	94
114	Bayesian Semiparametric Cure Rate Model with an Unknown Threshold. <i>Scandinavian Journal of Statistics</i> , 2008, 35, 540-556.	1.4	13
115	Cure Rate Model With Mismeasured Covariates Under Transformation. <i>Journal of the American Statistical Association</i> , 2008, 103, 743-756.	3.1	22
116	Partially Linear Additive Hazards Regression With Varying Coefficients. <i>Journal of the American Statistical Association</i> , 2008, 103, 1200-1213.	3.1	17
117	Power-Transformed Linear Quantile Regression With Censored Data. <i>Journal of the American Statistical Association</i> , 2008, 103, 1214-1224.	3.1	29
118	Comparison of Ductal Lavage and Random Periareolar Fine Needle Aspiration as Tissue Acquisition Methods in Early Breast Cancer Prevention Trials. <i>Clinical Cancer Research</i> , 2007, 13, 4943-4948.	7.0	27
119	Local likelihood with time-varying additive hazards model. <i>Canadian Journal of Statistics</i> , 2007, 35, 321-337.	0.9	4
120	Novel Clinical Trial Designs for Treatment of Ductal Carcinoma In Situ of the Breast with Trastuzumab (Herceptin). <i>Breast Journal</i> , 2007, 13, 72-75.	1.0	21
121	Marginal Analysis of Correlated Failure Time Data with Informative Cluster Sizes. <i>Biometrics</i> , 2007, 63, 663-672.	1.4	38
122	Model checking for additive hazards model with multivariate survival data. <i>Journal of Multivariate Analysis</i> , 2007, 98, 1018-1032.	1.0	13
123	Semiparametric Transformation Models for Survival Data With a Cure Fraction. <i>Journal of the American Statistical Association</i> , 2006, 101, 670-684.	3.1	101
124	Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios. <i>Biometrics</i> , 2006, 62, 777-787.	1.4	142
125	Correlation of cytologic findings and chromosomal instability detected by fluorescence in situ hybridization in breast fine-needle aspiration specimens from women at high risk for breast cancer. <i>Modern Pathology</i> , 2006, 19, 622-629.	5.5	25
126	Upregulation and activation of PKC $\zeta$ by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC $\zeta$ and Src inhibitors. <i>Oncogene</i> , 2006, 25, 3286-3295.	5.9	90



#	ARTICLE	IF	CITATIONS
127	Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. <i>Cancer</i> , 2006, 107, 1348-1354.	4.1	140
128	Efficient Algorithm for Computing Maximum Likelihood Estimates in Linear Transformation Models. <i>Journal of Computational and Graphical Statistics</i> , 2006, 15, 228-245.	1.7	6
129	ErbB2 Increases Vascular Endothelial Growth Factor Protein Synthesis via Activation of Mammalian Target of Rapamycin/p70S6K Leading to Increased Angiogenesis and Spontaneous Metastasis of Human Breast Cancer Cells. <i>Cancer Research</i> , 2006, 66, 2028-2037.	0.9	182
130	Root Canal Filled Versus Non-Root Canal Filled Teeth: A Retrospective Comparison of Survival Times. <i>Journal of Public Health Dentistry</i> , 2005, 65, 90-96.	1.2	164
131	A General Class of Bayesian Survival Models with Zero and Nonzero Cure Fractions. <i>Biometrics</i> , 2005, 61, 403-412.	1.4	33
132	Adaptive Design and Estimation in Randomized Clinical Trials with Correlated Observations. <i>Biometrics</i> , 2005, 61, 362-369.	1.4	10
133	Bayesian Cure Rate Frailty Models with Application to a Root Canal Therapy Study. <i>Biometrics</i> , 2005, 61, 552-558.	1.4	29
134	Quantile Regression Models with Multivariate Failure Time Data. <i>Biometrics</i> , 2005, 61, 151-161.	1.4	40
135	A Class of Bayesian Shared Gamma Frailty Models with Multivariate Failure Time Data. <i>Biometrics</i> , 2005, 61, 208-216.	1.4	26
136	Cure rate models: A unified approach. <i>Canadian Journal of Statistics</i> , 2005, 33, 559-570.	0.9	125
137	Pair Chart Test for an Early Survival Difference. <i>Lifetime Data Analysis</i> , 2005, 11, 117-129.	0.9	1
138	Self-Designing Trial Combined with Classical Group Sequential Monitoring. <i>Journal of Biopharmaceutical Statistics</i> , 2005, 15, 667-675.	0.8	14
139	Maximum Likelihood Estimation for the Proportional Odds Model With Random Effects. <i>Journal of the American Statistical Association</i> , 2005, 100, 470-483.	3.1	43
140	Inference for a Class of Transformed Hazards Models. <i>Journal of the American Statistical Association</i> , 2005, 100, 1000-1008.	3.1	16
141	Two Simulation Methods for Constructing Confidence Bands Under the Additive Risk Model. <i>Journal of Biopharmaceutical Statistics</i> , 2004, 14, 389-402.	0.8	4
142	Additive hazards model with multivariate failure time data. <i>Biometrika</i> , 2004, 91, 801-818.	2.4	51
143	Reconstructing the Kaplan-Meier Estimator as an M-estimator. <i>American Statistician</i> , 0, , 1-14.	1.6	1
144	Triangular Concordance Learning of Networks. <i>Journal of Computational and Graphical Statistics</i> , 0, , 1-32.	1.7	0